Livalo Acute Myocardial Infarction Study (LAMIS)
Completed
- Conditions
- Acute Myocardial Infarction
- Registration Number
- NCT01265706
- Lead Sponsor
- JW Pharmaceutical
- Brief Summary
This study is performed to observe the incidence of major cardiovascular events in Korean patients with AMI after giving pitavastatin 2mg and 4mg longer than 1 year.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
-
Patients with STEMI, NSTEMI
-
Patients satisfying at least one of the followings
- Patients with LDL-C ≥ 130 mg/dL
- Patients with LDL-C ≥ 100 mg/dL who are regarded as required cholesterol lowering therapy by the investigator
- Patients taking statin are required continuous cholesterol lowering therapy
-
Patients satisfying at least two of the followings
- The change of Ischemic ECG
- CK, CK-MB, Troponin-I increased more than two times
- The symptom of ACS
Exclusion Criteria
- Patients with in-stent restenosis after PCI or coronary artery bypass
- Patients with cardiogenic shock
- Patients with severe heart failure (Left ventricular ejection fraction is less than 30%)
- Patients who are taking cyclosporine
- Patients who experienced hypersensitivity to pitavastatin
- Patients under dialysis treatment
- Patients who are participating other clinical trials
- Patients who can not stop taking concomitant drugs
- Pregnant or lactating women or suspected pregnancy
- Patients who are regarded as ineligible for this study by the investigator
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of TLR-MACE for 1 year after enrollment 1 year after enrollment
- Secondary Outcome Measures
Name Time Method Incidence of TVR-MACE for 1 year after enrollment 1 year after enrollment
Trial Locations
- Locations (1)
Chonnam National University Hospital
🇰🇷Gwangju, Korea, Republic of